Plain-English translation of NCT06957808 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial investigates whether diroximel fumarate can boost a naturally occurring protective chemical in your brain called glutathione. Researchers believe this chemical may play a role in schizophrenia, and they want to see if this medication can safely increase it. The study involves taking the medication for several weeks while having brain scans and blood tests to measure changes.
People with schizophrenia may have lower levels of a protective brain chemical that helps protect nerve cells from damage. This medication has been used for other conditions, and researchers want to explore whether it could help support brain function in schizophrenia as an additional treatment alongside your regular antipsychotic medication.
You likely qualify if…
You likely don't qualify if…
You would first take the medication openly for two weeks, starting at a lower dose that increases at day 8. After this first phase, you would have the option to continue into a second phase where you would randomly receive either the medication or a placebo (fake pill) for another two weeks, without knowing which one you're taking. Throughout the study, you would have baseline blood tests, brain scans (MRI), brain electrical activity recordings (EEG), and symptom rating scales done at three time points: at the start, after the first two weeks, and after the full four weeks.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United Kingdom